Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Refractory Germ Cell Tumors
NCT04876456Phase 2Completed
- Start
- Jun 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in germ cell tumor (GCT). Started Jun 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT04876456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876456.